The Increasing Investments in R&D to Foster the Growth of the US Pharmaceutical Contract Manufacturing

Published: Dec 2019

The US pharmaceutical contract manufacturing is anticipated to grow at a considerable of 4.8% CAGR during the forecast period (2021-2027). The rising investments in R&D is one of the prime factors affecting and driving the market. In the US the spending in R&D is more in pharmaceutical and biotechnology market. The outsourcing of services by companies dealing in pharma sector in the US has increased in order to improve their margins related to profits. For this purpose, the companies are investing more in R&D due to increasing technological complexity with regards to development of drugs along with inject-able and sterile liquid dose to form. 

Browse the full report description of "US Pharmaceutical Contract Manufacturing Market Research By Category (Human Based Drugs and Animals Based Drugs), By Product (Over-The-Counter (OTC) Drugs, Active Pharmaceutical Ingredients (API), Finished Dosage Formulation and Other), and By Services (Manufacturing Services, Non-Clinical Services and Research and Development) Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/us-pharmaceutical-contract-manufacturing-market

To gain on the opportunity key players operating in the US pharmaceutical contract manufacturing had been adopting strategy such as new launches in the country.  For instance, in November 2020, Catalent, Inc. which is one of the providers of advanced delivery technology along with manufacturing solutions for consumer health products and various therapies have notified the acquisition of bone therapeutics cell therapy manufacturing subsidiary named as Skeletal Cell Therapy Support SA (SCTS). This will enable the company to expand its capabilities related to cell therapy.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Category

o By Product

o By Services

  • Competitive Landscape- AbbVie Inc., Cardinal Health., Catalent, Inc., Pfizer Inc., and Thermo Fisher Scientific Inc.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

US Pharmaceutical Contract Manufacturing

By Category

    • Human Based Drugs 

    • Animals Based Drugs

By Product

    • Over-The-Counter (OTC) Drugs 

    • Active Pharmaceutical Ingredients (API)

    • Finished Dosage Formulation 

    • Other

By Services 

    • Manufacturing Services 

    • Non-Clinical Services 

    • Research and Development 

To learn more about this report request a sample copy @  https://www.omrglobal.com/request-sample/us-pharmaceutical-contract-manufacturing-market